Teva Pharmaceutical Industries Articles
Cephalon and Teva settle Provigil patent dispute
19 December 2005
Teva gets tentative US OK for generic zaleplon
5 December 2005
Antares to supply injectables to Teva
5 December 2005
Teva invests in Clal and CureTech; opens Jerusalem plant
19 September 2005
Sanofi-Aventis gets competition from Teva and Barr Allegra generics deal
12 September 2005
Teva gets OK for generic Paxil
22 August 2005
Teva gets tentative appro for risedronate
22 August 2005
Teva to continue talks with FDA on Agilect NDA
15 August 2005
Teva's 2nd-qtr lifted by non-US business
8 August 2005
Tentative US approval for Teva's tramadol
25 July 2005
FDA OKs Teva's generic mirtazapine
11 July 2005
Teva/Active Biotech submit laquinimod IND
4 July 2005
Positive comparative data on Copaxone
20 June 2005
Teva gets FDA OK for generic clarithromycin
23 May 2005
Final FDA approval for Teva's fenofibrate
23 May 2005
Teva 1st-qtr net profit leaps 26%
16 May 2005
Teva gets clearance for clozapine in USA
9 May 2005
Laquinimod in MS data now published
28 March 2005
Encouraging data for Agilect
14 March 2005
Teva/Lundbeck's Azilect cleared for PD in EU
28 February 2005
Teva forms JV with Gamida-Cell
28 February 2005
Alpharma settles gabapentin exclusivity litigation
21 February 2005
Teva gains tentative US OK for generic levofloxacin
21 February 2005
Teva's 4th-qtr income soars 40%
21 February 2005
Generic approvals for Mylan and Teva
21 February 2005
Savient in partial deal with Novo Nordisk on hGH patent
7 February 2005
Teva gets FDA OK for fluconazole injection
24 January 2005
Teva's Azilect gets first approval in Israel
10 January 2005
Sicor re-acquires Calcitrol rights from aaiPharma
10 January 2005
Teva's increases repurchase program up to $600M
10 January 2005
Merck & Co slams Teva for response to petition
20 December 2004
Codexis in research accord with Teva on pharma biosyntheses
20 December 2004
Teva's 3rd-qtr 2004 sales rocket 53%
22 November 2004
Copaxone 3rd-qtr sales rise 34% to $242M
1 November 2004
Teva and Biovail resolve arbitration
11 October 2004
Positive data for Teva's Agilect
13 September 2004
Teva to repurchase $300M securities
13 September 2004
GSK prevails in Teva Zofran patent dispute
30 August 2004
Teva to buy Pfizer's Italian generics unit
23 August 2004
Teva and Savient get favorable ruling on rHGH
16 August 2004
Teva gains US appro for terbutaline
26 July 2004
FDA approvable letter for Teva's Agilect
12 July 2004
Teva pays $5M for Active Bio's MS drug
21 June 2004
Four drugmakers gain US appro for generic Cipro
14 June 2004
Teva commercializing generic oxycodone 80mg in USA
5 April 2004
Teva comments on Biovail dispute
8 March 2004
Teva reports record annual sales of $3.3B
1 March 2004
Israeli drug exports "to rise 20% this year"
1 March 2004
Teva prices $1 billion debenture offering; closes Sicor deal
2 February 2004
Company news briefs
26 January 2004
Savient Pharma claims Teva interest
13 October 2003
Aventis/Teva's Copaxone fully available in France
6 October 2003
Teva gains US approval for generic ofloxacin
8 September 2003
Teva announces conversion period for debentures
11 August 2003
Teva gains rights to GSK leukemia drug
7 July 2003
US generics approvals for Teva and B&L
16 June 2003
Teva and Eisai link up on CNS drug rasagiline
19 May 2003
Teva's generic Univasc cleared in USA
19 May 2003
Teva settles nabumetone litigation with GSK
5 May 2003
Teva gets go-ahead for Vicoprofen generic
21 April 2003
Teva and Novartis strike deal with S-P
31 March 2003
OGS says Teva files Zavesca in Israel
27 January 2003
Lek takes on GSK's Augmentin in USA
13 January 2003
Teva gets tentative FDA go-ahead for generic Fosamax
6 January 2003
Teva completes Bayer Classics purchase
8 July 2002
Teva completes Honeywell pharma acquisition
1 July 2002
Draxis prices secondary offering of 4.2M shares
24 June 2002
Teva gets initial OK for generic Pravachol
27 May 2002
Copaxone driving Teva revenue growth
6 May 2002
Major increase in net losses at OGS
1 April 2002
Major increase in net losses at OGS
1 April 2002
Teva gets tentative US approval for quinapril
18 February 2002
Impax revenue for 2001 rises 54%
11 February 2002
Teva bids for Bayer's French generic ops
11 February 2002
Teva gets tentative OK for generic Cipro
7 January 2002
Teva has final FDA OK for generic Mevacor
7 January 2002
Teva has final FDA OK for generic Mevacor
19 December 2001
Teva to sell OGS' Vevesca in Israel
20 November 2001
Teva not buying Faulding injectibles
16 November 2001
Teva gets first OK for generic Rocaltrol in USA
15 October 2001
Teva posts equivocal data on oral Copaxone - UPDATE
20 September 2001
Teva posts equivocal data on oral Copaxone
17 September 2001
Teva wins Relafen case; generic launch imminent
16 August 2001
180-day exclusivity for Teva's famotidine
6 June 2001
Copaxone driving profit growth at Teva
4 May 2001
Teva launches MS drug Copaxone in UK
7 December 2000
Biovail gets US OK for first generic Adalat CC
5 December 2000
Teva denies rumors of Mylan takeover
3 October 2000
Hungary's APV sells stake in Human to Teva
7 April 2000
First Voltaren XL generic approved and launched in USA
24 February 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
